Isler Burcu, Özer Berna, Çınar Güle, Aslan Abdullah Tarık, Vatansever Cansel, Falconer Caitlin, Dolapçı İştar, Şimşek Funda, Tülek Necla, Demirkaya Hamiyet, Menekşe Şirin, Akalin Halis, Balkan İlker İnanç, Aydın Mehtap, Tigen Elif Tükenmez, Demir Safiye Koçulu, Kapmaz Mahir, Keske Şiran, Doğan Özlem, Arabacı Çiğdem, Yağcı Serap, Hazırolan Gülşen, Bakır Veli Oğuzalp, Gönen Mehmet, Chatfield Mark D, Forde Brian, Saltoğlu Neşe, Azap Alpay, Azap Özlem, Akova Murat, Paterson David L, Can Füsun, Ergönül Önder
Centre for Clinical Research, University of Queensland, Brisbane, Australia.
Clinical Microbiology, School of Medicine, Koç University, Istanbul, Turkey.
Eur J Clin Microbiol Infect Dis. 2022 May;41(5):841-847. doi: 10.1007/s10096-022-04425-4. Epub 2022 Mar 17.
A prospective, multicentre observational cohort study of carbapenem-resistant Klebsiella spp. (CRK) bloodstream infections was conducted in Turkey from June 2018 to June 2019. One hundred eighty-seven patients were recruited. Single OXA-48-like carbapenemases predominated (75%), followed by OXA-48-like/NDM coproducers (16%). OXA-232 constituted 31% of all OXA-48-like carbapenemases and was mainly carried on ST2096. Thirty-day mortality was 44% overall and 51% for ST2096. In the multivariate cox regression analysis, SOFA score and immunosuppression were significant predictors of 30-day mortality and ST2096 had a non-significant effect. All OXA-48-like producers remained susceptible to ceftazidime-avibactam.
2018年6月至2019年6月在土耳其开展了一项关于耐碳青霉烯类克雷伯菌属（CRK）血流感染的前瞻性、多中心观察性队列研究。招募了187名患者。单一OXA-48样碳青霉烯酶占主导（75%），其次是OXA-48样/NDM共生产者（16%）。OXA-232占所有OXA-48样碳青霉烯酶的31%，主要携带于ST2096。总体30天死亡率为44%，ST2096为51%。在多变量cox回归分析中，序贯器官衰竭评估（SOFA）评分和免疫抑制是30天死亡率的显著预测因素，而ST2096的影响不显著。所有OXA-48样生产者对头孢他啶-阿维巴坦仍敏感。
